A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin/Lucentis) Compared With Intraocular Triamcinolone (Volon A) in Patients With Clinical Significant Diabetic Macular Edema

Trial Profile

A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin/Lucentis) Compared With Intraocular Triamcinolone (Volon A) in Patients With Clinical Significant Diabetic Macular Edema

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Ranibizumab (Primary) ; Triamcinolone
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms TRIASTIN
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 31 May 2013 Planned end date changed from 1 Oct 2009 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top